You are viewing the site in preview mode

Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study

Fig. 3

As of the follow-up date from January 1, 2021, to March 1, 2024, among the 21 patients with advanced LUAD harboring EGFR ex20ins mutations, 13 had received prior systemic therapy, while 8 had not. Compared with patients who received prior systemic therapy, those who did not had significantly longer PFS (A), TTF (B), and OS (C). Of the 21 patients, 10 had central nervous system (CNS) metastasis, and 11 did not. Patients without CNS metastasis tended to have prolonged PFS (D), TTF (E), and OS (F) compared to those with CNS metastasis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us